Digitisation | June 28, 2022
Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
Strengthens investment in channels of the future to expand patient reach
Strengthens investment in channels of the future to expand patient reach
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Subscribe To Our Newsletter & Stay Updated
